Cytokinetics, Incorporated
CYTK · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1,936 | $66,769 | $1,579 | $16,927 |
| % Growth | -97.1% | 4,128.6% | -90.7% | – |
| Cost of Goods Sold | $2,679 | $2,285 | $99,841 | $93,629 |
| Gross Profit | -$743 | $64,484 | -$98,262 | -$76,702 |
| % Margin | -38.4% | 96.6% | -6,223.1% | -453.1% |
| R&D Expenses | $99,233 | $112,554 | $99,841 | $93,629 |
| G&A Expenses | $69,458 | $65,721 | $57,369 | $62,338 |
| SG&A Expenses | $69,458 | $65,721 | $57,369 | $62,338 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2,679 | -$2,285 | -$99,841 | -$93,629 |
| Operating Expenses | $166,012 | $175,990 | $57,369 | $62,338 |
| Operating Income | -$166,755 | -$111,506 | -$155,631 | -$139,040 |
| % Margin | -8,613.4% | -167% | -9,856.3% | -821.4% |
| Other Income/Exp. Net | -$139,423 | -$22,864 | -$5,745 | -$10,980 |
| Pre-Tax Income | -$306,178 | -$134,370 | -$161,376 | -$150,020 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$306,178 | -$134,370 | -$161,376 | -$150,020 |
| % Margin | -15,815% | -201.2% | -10,220.1% | -886.3% |
| EPS | -2.55 | -1.12 | -1.36 | -1.27 |
| % Growth | -127.7% | 17.6% | -7.1% | – |
| EPS Diluted | -2.55 | -1.12 | -1.36 | -1.27 |
| Weighted Avg Shares Out | 119,982 | 119,457 | 118,496 | 118,075 |
| Weighted Avg Shares Out Dil | 119,982 | 119,457 | 118,496 | 118,075 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10,248 | $13,001 | $13,701 | $15,014 |
| Interest Expense | $26,322 | $24,265 | $22,946 | $22,594 |
| Depreciation & Amortization | $2,679 | $2,285 | $2,300 | $2,383 |
| EBITDA | -$277,177 | -$107,820 | -$136,130 | -$125,043 |
| % Margin | -14,317% | -161.5% | -8,621.3% | -738.7% |